Objective. To assess cognitive performance of chronic pain (CP) patients diagnosed with three types of pain-neuropathic pain (NP), musculoskeletal (MSK), and fibromyalgia (FM)-and to analyze the factors influencing cognitive difficulties in each group.
Introduction
Chronic pain (CP) may produce physical and psychological disability [1] and is associated with serious comorbidities like anxiety and depression [2] or poor V C 2017 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com quality of sleep [3] . These disorders have been suggested to represent distinct constructs that are moderately correlated in CP patients [4, 5] .
In terms of cognitive performance, CP patients often complain of loss of concentration and memory difficulties [6] [7] [8] , and a deterioration in decision-making or attention has been described in these subjects [9] . Neuroimaging techniques have greatly advanced our understanding of the interaction between pain and cognitive processing at a neuro-anatomical level, showing that CP alters normal processing in the nervous system, which could account for deficits in cognitive function [10, 11] .
The impact of depression, anxiety, and sleep disturbances on cognitive performance has previously been studied [12] [13] [14] [15] , and results suggest that CP may account for depression, which in turn may produce impairment of multiple cognitive abilities [16] . Similarly, anxiety and stress may interfere with performance in neuropsychological tasks [17] , and it seems that a reduction in sleep quality may influence cognitive functioning [18, 19] .
Some researchers have noted that sleep disturbance, affective distress, or some medication use may modulate the effect of pain or may even be more important than pain itself in explaining performance deficits [11] . Nonetheless, other authors have shown that the intensity and duration of pain exert an important role in cognitive performance, regardless of the factors discussed above [20, 21] . Moreover, several authors have shown differences in cognitive performance among different groups of pain, suggesting that cognitive function might be impaired not only by the presence of pain, but also by a direct effect of the type of pain itself. Thus, it has been shown that patients with widespread pain (this is the case with fibromyalgia) present significantly more concentration and memory difficulties than patients with clearly localized pain [22] . In fact, comparing a group of patients with fibromyalgia (FM) with two groups suffering from neuropathic pain (NP) and mixed pain (MP), the patients with FM were associated with a higher frequency of cognitive impairment, and this cognitive impairment remained higher after adjusting for the presence of anxiety and depressive symptoms [23] . Another study showed that NP patients with symptoms of depression showed a significantly higher prevalence of cognitive impairment than this same type of patient in a mixed pain subgroup [24] . The reasons underlying these differences are vague and inconclusive. Unfortunately, the literature does not provide the opportunity to make a head-to-head comparison between different pain conditions [25] .
Gaining a better understanding of cognitive function performance in each group of patients and the associated factors that underpin it may provide additional information relevant to the etiology and maintenance of symptoms in CP patients [26] . Accordingly, in this study we aimed to evaluate the cognitive performance of patients that suffer neuropathic (NP) and musculoskeletal (MSK) pain and fibromyalgia (FM), comparing the results with those from a group of pain-free subjects. In addition, we set out to analyze the factors related to the cognitive performance of each group of CP patients. To address these objectives, we first hypothesized that cognitive performance would be affected more strongly in CP patients than in pain-free subjects and that differences would also exist between the three groups of CP patients. We also hypothesized that the effect of sleep and mood disorders on cognitive performance might differ in accordance with the cause of the CP.
Methods

Subjects
Chronic pain patients from the Chronic Pain Unit at the "Puerta del Mar" University Hospital in Cadiz, Spain (admitting 1,200 patients a year), were studied, including 254 patients suffering nononcological pain (visual analog scale [VAS] > 0) of at least three months' duration (IASP, 1986) . Based on radiological and clinical criteria, the patients were diagnosed with NP or MSK pain or FM in accordance with the American College of Rheumatology [ACR] criteria [27] . In addition, 72 control subjects (CS) free of pain were recruited from a primary care setting. Both the CP patients and CS were able to complete the questionnaires and tests, and they were excluded if they had any previously diagnosed dementia or cognitive impairment. The patients were enrolled to participate in the study once they had signed an informed consent form. The study protocol was approved by the Clinical Research Ethics Committee of the "Puerta del Mar" University Hospital (C adiz, Spain), ensuring compliance with the standards of good clinical practice.
Assessment
Sociodemographic and clinical information (the existence of diagnosed comorbidities in the subjects' medical history and cardiovascular risk factors such as diabetes, hypercholesterolemia, and/or hypertension) was collected using a structured questionnaire and from the patients' clinical records. Information was also collected regarding the medication that the patients were taking at the time of the evaluation. We were particularly interested in recording any medication that might affect cognitive function. The selection of the drugs specifically affecting cognitive function was based on a prepared list based on the technical data sheets of the products registered by the Spanish Agency for Medications and Healthcare Products. Specifically, the information collected addressed five groups of drugs commonly used in the treatment of chronic pain: antidepressants, benzodiazepines (BZD), anticonvulsants, opioids, and nonsteroidal anti-inflammatory drugs (NSAIDs).
The characteristics of pain were also collected from the CP patients: diagnosis and type, location, intensity (measured using a VAS of 0-10) and duration (months).
Cognitive function was assessed using "Test Your Memory" (TYM), a scale previously translated and adapted into the Spanish language [28, 29] . TYM involves completing a two-sided sheet that contains different tasks to assess 10 cognitive domains. The items contained in TYM include tasks of orientation, copying, retrograde and anterograde memory, calculation, phonemic verbal fluency, similarities, object naming, visuospatial function (including clock drawing), and executive function. This test is self-administered under supervision, and it takes about five minutes to complete. It gives a maximum score of 50 points-the higher the score, the better the cognitive performance. Compared with other screening instruments, the TYM has been shown to be very sensitive and specific to detecting cognitive impairment and dementia [30, 31] and to have more discriminative power to distinguish people with modest impairment (sensitivity and specificity were 96% and 91% for diagnosing Alzheimer's disease, and 76% and 74% for diagnosing mild cognitive impairment) from those with normal cognitive functioning [32, 33] .
Mood status (anxiety and depression) was assessed using the Hospital Anxiety and Depression scale (HADs) [34, 35] , a valid and reliable instrument recommended to assess the emotional status of CP patients [36] . The HADs is a brief measure that consists of a seven-item anxiety subscale and a seven-item depression subscale. Each item is scored on a four-point Likert scale, giving maximum subscale scores of 21 for depression and anxiety. A score above 10 in either of the subscales indicates clinically significant anxiety or depression [37] . The HADs has been shown to possess satisfactory psychometric properties for detecting the presence of anxiety and depression in the Spanish population [38] and in patients with painful pathologies [39, 40] .
The Sleep Problem Index 9 (I-9) of the MOS (Medical Outcome Study) sleep scale [41] were used to assess the patients' sleep quality. The MOS sleep questionnaire is a patient-reported measure consisting of 12 items that assess the key constructs of sleep. In particular, the Sleep Problems Index is constructed around nine items to provide a composite score within a possible range of 0 to 100, where higher scores indicate more sleep problems. Likewise, as part of the MOS sleep scale, the quantity of sleep was reported by patients as the average number of hours they slept each night, information that was subsequently categorized as optimal sleep (between seven and eight hours of sleep per night) and nonoptimal sleep (less than seven hours or more than eight hours of sleep per night) [41] . The Spanish version has been assessed in patients with pain of broad etiology [42, 43] . These studies showed good psychometric properties and that this scale is an appropriate measure of pain-related sleep problems.
Analysis
A descriptive analysis of the data was performed, and the associations between the variables were analyzed with a v 2 test. When the Kolmogorov-Smirnov test demonstrated a non-normal distribution, either the Mann-Whitney U-test or Kruskal-Wallis H test was used. For all the tests, P values of 0.05 or less were considered significant.
To compare the cognitive performance results between the cases and controls and between the three groups of CP patients and to eliminate the potential confounders related to differences in sex, age, academic level, anxiety and depression scores, quality of sleep, treatment with drugs that potentially affect cognitive function, and cardiovascular risk factors, the scores of the TYM were adjusted by these variables.
In addition, four different linear regression models (LRMs) were used to assess the variables associated with cognitive performance in the whole sample of CP patients and in each of the three CP groups (NP, MSK, FM). The dependent variable in the four models was the TYM score, and the independent variables included in the analysis were the sociodemographic variables (sex, age, educational level), being diagnosed with a comorbidity, the medications potentially affecting cognitive performance, the intensity and duration of the pain, and the scores in the HADs-A, HADs-D, and I-9 scales. In order to expand the understanding of the relationships among the variables in the models and to allow more hypotheses to be tested, two considerations were made to construct the models. First, taking into account that some studies have shown that patients suffering from pain of long duration are able to adapt better to the pain [44] , we hypothesized that this adaptation may have a positive effect on cognitive function, so after testing that the relationship between the duration of pain and cognitive performance was not linear, we tested for a possible quadratic relationship. As it proved to be significant, the duration of pain was introduced into the regression models as a linear and as a quadratic continuous variable. Second, as the role of depression as a moderating variable in pain disability has been hypothesized previously, the interaction between depression and pain intensity and how they affected cognitive function were analyzed in the models.
Results
Population Characteristics
This study was carried out on a group of 326 subjects, including 104 patients diagnosed with NP, 99 with MSK pain, 51 with FM, and 72 CS. A comparison of the main variables analyzed in the study was made between the CP patients and the CS group, and between the three CP groups (Table 1 ). In the whole sample of CP patients, 63.8% were women with a mean age of 47.4 years (SD ¼ 8.8, range ¼ 18-60). It was also noteworthy that there was a higher percentage of individuals with no academic qualifications in the group of CP subjects compared with the pain-free group (11.8 vs 5.6%, P < 0.001) and that there was a high proportion of women among the FM patients (96.1%, only two men), with a higher mean age in this group. There was wide variability between the groups regarding the duration of pain, ranging from three months to 40 years (mean ¼ 108.5 months, SD ¼ 97.6), although the mean intensity of pain in each group was very similar (Table 1) . No differences were found between men and women in cognitive performance, intensity and duration of pain, anxiety, depression, and sleep quality in the NP and MSK pain groups. It was not possible to detect differences in the FM group because only two patients were men (data not shown).
There was a high incidence of comorbidities among the CP patients, especially in the FM group, where more than 90% of the subjects referred to another associated condition. The use of medication that could potentially impair cognitive performance was higher in the CP patients than in the CS, especially in the NP patients (89.4%).
There were differences of more than five points in the HAD scores between the CP and CS groups, the scores for anxiety and depression being greater in the CP patients (Table 1) , especially the anxiety scores in those subjects diagnosed with FM. Sleep quality (I-9 MOS) was worse in the patients with CP than in the CS group (Table 1) , although the scores in this scale did not differ notably between the groups of CP patients.
Cognitive Outcomes
As hypothesized, the mean TYM scores were lower in the group of CP patients vs controls, with a difference between them of 3.43 points (P < 0.001) (Figure 1 ). Contrary to our predictions, we found no differences in the TYM scores among the three groups of chronic pain patients ( Figure 1 ).
Regression Analyses
When the whole sample of CP patients was analyzed, the factor most strongly associated with cognitive performance was depression, although it was also associated with age and educational level, as expected. As such, an inverse relationship was evident to the extent that for each point increase in the HAD-D score there was a decrease of almost 0.3 in the TYM scores ( Table 2) . The relationship between cognitive performance and age, educational level and depression was also observed when each of the CP pain groups was analyzed, except for the FM patients where the age variable did not prove to be important. Accordingly, the TYM score decreased 1.2 points for every 10-year increase in the age of the NP patients and 0.9 points in the MSK group (Table 2) . Moreover, the higher the educational level, the Figure 1 Test Your Memory mean scores according to different groups. greater the score registered in terms of cognitive performance (or alternatively, the lower the educational level, the worse the cognitive performance); and higher values in the depression subscale (HADs-D) were associated with worse cognitive performance, especially in the FM patients (ß ¼ -1.01, SE ¼ 0.42, 95% confidence interval [CI] ¼ -1.05 to -2.38, P ¼ 0.022) ( Table 2 ).
Pain and Factors Related to Cognition
Also important was that the relationship between the duration of pain and the TYM score in the patients with NP was not linear but rather U-shaped (a quadratic relationship). As such, the TYM score decreased (i.e., cognitive performance was worse) as the duration of pain increased up to nearly nine years (107.14 months) (Figure 2 ), after which the TYM scores began to increase (better cognitive performance) with the longer duration of pain ( Figure 2 ).
In addition, the intensity of pain did not significantly affect cognitive performance in patients with FM (P ¼ 0.435) ( Table 2) , although this variable did interact with depression (INTxDEPRE), whereby as pain intensity (VAS score) and depression (HAD-D) increased, a greater deterioration in cognitive performance was evident (lower TYM score; ß(INTxDEPRE) ¼ -0.51 -1.01 þ 0.13 ¼ -1.39, P ¼ 0.047). This effect was stronger than the effect of either depression or pain intensity alone, although not as great as their sum. Thus, it appears that depression significantly moderates the relationship between pain intensity and cognitive performance in FM patients.
Anxiety and sleep were not related with cognitive performance in any of the groups of CP patients.
Discussion
The main objective of this study was to determine the cognitive performance of three groups of CP patients and to compare them with a group of pain-free subjects, and also to analyze the associated factors in each group. The results demonstrated that cognition, as measured by the TYM scale, was inferior in patients with CP compared with the control group. Moreover, no significant differences were observed regarding the TYM scores in any group of CP patients, although the FM group scored lower in the test. This means that the presence of pain affected cognitive functions similarly in all three types of pain. Nevertheless, and as is revealed in our study, there were some significant factors influencing cognition that, interestingly, depend on the type of pain.
Regarding these factors, the results revealed that depression was a factor associated with cognitive performance in the CP patients, although this association varied between groups. Specifically, in MSK patients, depression was the only factor that affected cognitive performance, while in the FM patients the effect differed in accordance with the pain intensity. Depression was not significantly related to cognitive performance in the NP patients. Nevertheless, a nonlinear relationship was observed in this group between the duration of pain and cognitive performance, whereby the effect was weaker when the pain was of a shorter or longer duration than nine years.
In line with previous results, we found that the presence of affective disorders has a negative relationship with Figure 2 Quadratic relationship between pain duration and Test Your Memory score (NP: N ¼ 104). * TYM scores were adjusted for potential confounding factors (sex, age, academic level, anxiety and depression, sleep quality, drug therapies that potentially affect cognitive function and cardiovascular risk factors).
cognitive performance in CP patients. There is evidence that the depression experienced by a patient is responsible for a deterioration in cognitive performance, either due to the lack of effort and interest of the patients in carrying out the cognitive tasks [18] or due to the interference from the depressive state on cognitive processing, which limits the subject's attention and hence hinders their cognitive function [45, 46] . In a related study, Suhr noted that FM patients report more severe cognitive impairment when compared with other chronic pain patients and healthy controls. They found that depression and fatigue were significantly associated with cognitive complaints for memory and psychomotor function in FM [47] . Taken together, these data suggest that depression may account for the deficits in cognition observed for FM patients in previous studies.
Nevertheless, depression was not the only factor responsible for the cognitive decline in the CP patients studied as it was directly related to the intensity and the duration of pain. Conversely and unexpectedly, anxiety, an indicator of psychological stress known to influence cognitive function [13] , did not appear to be a relevant factor in this study.
The relationship established in FM patients between pain intensity and cognitive function was also interesting as those patients reporting greater pain also performed worse in the cognitive test, depression apparently moderating this relationship. This effect-pain positively related to depression and negatively related to cognitive performance-is in line with findings in the literature where, in some cases, depression mediates (or confounds) the relationship between pain intensity and cognitive performance [16] . In an attempt to give an explanation for this relationship (mediated), it has been speculated that high levels of pain may lead patients to engage in negative self-destructive rumination (as a symptom of depression), impairing their performance in tasks that require substantial cognitive resources [16] . These results highlight the importance of considering, especially in patients with FM, not only the control of the intensity of pain but the depressed mood of the patient at the same time.
Perception of pain has been described in FM as a factor playing an important role in the pain experience, and catastrophizing, chronic worry, hypervigilance, and fear have been shown to influence cognitive function in these subjects [48] . However, the way in which these factors affect patients suffering from other kinds of pain (not FM) is not clear, cognitive function and the variables related with it (anxiety, depression, intensity, duration of pain) possibly being affected in different ways. Although this hypothesis is plausible, it cannot be proven in this study as these variables were not measured.
The duration of pain also appears to affect the relationship between pain and cognition. NP patients experienced deteriorated cognitive performance as the duration of pain increased. Interestingly, from a given time point (107 months), the performance improved.
Other studies that have analyzed the relationship between these two variables have produced less conclusive results. While no relationship was observed in some studies [49, 50] , others encountered a linear relationship whereby the longer duration of the illness was correlated with poorer cognitive performance or an inverse relationship between pain duration and cognitive performance [51, 52] .
It is well known that although NP is diagnosed on the basis of well-established criteria and there are several scales to help with diagnosis, it appears to be difficult to diagnose [53] , and underdiagnoses are common in primary care [54] . At the onset, without explanation, pain is frequently misinterpreted as harm, prompting protective strategies that exacerbate disability [55] . In the same vein, these patients have been reported to have some difficulties coping with their disease at the beginning [56] . It probably takes longer for people with NP to conceptualize the problem and develop explanations that make sense of their pain, a factor that can mitigate its impact and consequently affect their cognitive performance. This hypothesis could be applied to the results found in our study and could explain the differences observed in the patients with NP.
Although our results should be interpreted with caution due to the transversal design of the study, as far as we are aware, there are no other studies in the literature in which a U-shaped relationship has been described between the duration of pain and cognitive performance.
As parallel results, it has been described that different psychosocial factors affect patients who are in different stages of a CP disease differently, the duration being considered a very important factor in the disease [57] . Over time, patients who are more able to assimilate and accommodate their chronic pain conditions in their lives experience less disability [58] , which may also be reflected in fewer cognitive deficits; alternatively, it also indicates that those with a longer duration of pain report greater acceptance. Finally, it has been proposed that situations that generate discomfort and suffering may be transitory in CP patients as they end up accepting and adjusting to their new circumstances [44] . Therefore, we conclude that, although pain tends to be considered a linear phenomenon [59] , investigating alternative relationships (nonlinear relationships) between CP and the factors that interact with it would appear to be of interest.
Unquestionably, we did not find the effect of sleep quality on cognitive function in any of the proposed models; however, as previous studies have indicated, the relationship between chronic pain and decreased cognitive functions can persist beyond possible differences in sleep quality [60, 61] . Therefore, it is possible that in our results the effect of sleep quality went unnoticed, given the potential effect of other variables. In addition, it is worth highlighting that although information about certain medication (anxiolytics, antidepressants) that could influence the results observed was controlled in the statistical analysis, this was not the case of other treatments such as cognitive behavioral therapy that could lead to bias in the results.
Apart from the clinical variables related to pain, age and the level of education were related to the cognitive performance of the patients in this study. These should be considered important factors that affect the interpretation of the final scores [62] , although this is not only applicable to patients with CP but also to all patients that undergo cognitive evaluations [63] . Indeed, age had a further negative impact on cognitive performance that was largely independent of pain and depression. It was also remarkable that no relationship was found between sex and cognitive function in any of the groups of patients analyzed (data not shown). This could be attributed to the fact that, unlike other studies [11, 19] , no differences were found between men and women in any of the variables analyzed (HADs-D, HADs-A, Index-9, pain intensity and duration).
Given the increased prevalence of cognitive impairment among individuals with chronic diseases and the consequences of this impairment on CP management, as well as adherence to medication and its negative effect on quality of life [64] , further research is needed in order to determine the type of cognitive impairment in different types of CP patients.
Strengths and Weaknesses of the Study
Our study includes a control group and three groups of patients with CP of distinct origins, which allows us to compare these groups and to determine which cognitive aspects are affected in each of them. Moreover, it should be noted that all the medications known to have a deleterious effect on cognitive performance were taken into account, which further validates the results obtained.
One important limitation to this study may be that the results obtained in the cognitive performance were assessed by the TYM. This instrument is a screening tool rather than a detailed neuropsychological assessment involving a battery of instruments. However, the time taken and the level of training required by the evaluator make this task much more complex. In addition, the TYM has proven to be a valid and reliable instrument in different clinical and cultural contexts [33, 65] , and especially in patients with chronic pain [29] .
Conclusions
The current findings provide a new perspective on the relationship between CP, affective disorders, and cognitive functioning, over and above that offered previously. The possibility of defining a cognitive profile for these patients and the need to analyze each group separately has been proposed. With respect to the factors that affect cognitive performance, depression has a significant impact on specific groups of pain patients, such as MSK and in FM. However, the intensity of pain only affected the FM patients and the duration of pain had a U-shaped association with cognitive performance in the NP group. In view of the results, we conclude that in the assessment of the cognitive function of patients with CP, the global assessment of variables related to mood and pain is necessary and that the analysis of the specific types of pain in each individual will provide more detailed information about how each case is affected. In addition, other nonlinear relationships between pain and cognitive impairment should be taken into consideration. This will enhance our understanding of pain mechanisms and improve the way patients are treated.
